Wilmington-based Pharmaceutical Product Development (PPD) recently achieved CEO Cancer Gold Standard reaccreditation from the nonprofit CEO Roundtable on Cancer.

PPD achieved the reaccreditation for maintaining a strong commitment to the health of company employees, a news release said.

The release said that PPD encourages employee participation in health and wellness programs, including cancer prevention and screening, nutrition coaching and fitness classes, to promote healthy lifestyles and empower employees to take an active role in managing their health.

“PPD is committed to the fight against cancer,” David Simmons, PPD chairman and CEO, said in a news release.

“As a global contract research organization with deep expertise in oncology, we are dedicated to helping  biopharmaceutical clients deliver safe treatments to patients more quickly, cost-effectively and with the highest possible quality. We’re pleased the CEO Roundtable on Cancer has recognized our efforts in employee health and wellness, and we applaud their worthy mission,” Simmons said.

PPD provides a tobacco-free workplace, health screenings, education and promotion of healthy lifestyles and other initiatives critical to helping detect and prevent cancer.

Nearly 200 private, nonprofit and government employers in a wide range of occupational categories have earned Gold Standard accreditation, including the National Cancer Institute (NCI) and a number of NCI-designated cancer centers.